- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03145207
PK and DPK of Lidocaine Dermal Products
June 24, 2020 updated by: Audra Stinchcomb, University of Maryland, Baltimore
Evaluation of Bioavailability of Lidocaine Dermal Products
This is a bioequivalence study to compare lidocaine release between a brand name and generic skin patches in healthy adults.
Study Overview
Detailed Description
This research study is intended to determine the effect of heat on lidocaine patches.
This study will use lidocaine patches (brand name and generic patches) that have been approved by the Food and Drug Administration (FDA) and are already sold to customers in the United States, and will not include any placebos.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- General Clinical Research Center (GCRC) at the University of
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men or non-pregnant, women who are of any ethnic background between the age of 18 and 45 years old.
- Subjects must be non-smokers (must have refrained from the use of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patches or electronic cigarettes) over the previous 2 months and are not currently using tobacco products.
- Provide written informed consent before initiation of any of the study procedures.
- Agrees not to participate in another clinical trial/study or to participate in an investigational drug study for at least 1 month after the last study session.
- Able to adhere to the study restrictions and protocol schedule.
- Able to participate in all study sessions.
- Has a volar forearm of either at least 24 cm (9.45 inches) in length or of sufficient size that can accommodate the formulations to be tested in a study area that begins at least 5 cm (1.97 inches) above the wrist and ends a minimum of 0.5 cm (0.197 inches) below the antecubital fossa (i.e., the bend in the arm at the elbow).
- Subjects have upper arms (minimum 28 cm (11 inch) circumference) large enough to allow for the placement of two 140 cm2 patches on one upper arm or one 140 cm2 patch on each upper arm.
- Subjects deemed to be healthy as judged by the MAI and determined by medical history, physical examination and medication history.
- Negative urine drug screening test.
- Have normal screening laboratories for WBC, CBC, Hgb, platelets, sodium, potassium, chloride, bicarbonate, BUN, creatinine, ALT and AST.
- Have normal screening laboratories for urine protein and urine glucose.
- Female subjects must be of non-childbearing potential (as defined as surgically sterile [i.e., history of hysterectomy or tubal ligation] or postmenopausal for more than 1 year), or if of childbearing potential must be non-pregnant at the time of enrollment and on the morning of each procedure day, and must agree to use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner.
- Agrees not to donate blood to a blood bank throughout participation in the study and at least 3 months after the last procedure day.
- Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute).
Have normal vital signs:
- Temperature 35-37.9°C (95-100.3°F)
- Systolic blood pressure 90-140 mmHg
- Diastolic blood pressure 60-90 mmHg
- Heart rate 55-100 beats per minute
- Respiration rate 12-20 breaths per minute
Exclusion Criteria:
- Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy test at enrollment or positive urine pregnancy test on the morning of each study session.
- Smokers (current use or use over the previous 2 months of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patches or electronic cigarettes).
- Participation in any ongoing investigational drug trial/study or clinical drug trial/study.
- History of chronic obstructive pulmonary disease or cor pulmonale, or substantially decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory depression.
- Active positive Hepatitis B, C and/or HIV serologies (see Appendix B).
- Known anemia.
- Positive urine drug screening test.
- Use of chronic prescription medication during the period 0 to 30 days; or over-the counter medication (e.g. antihistamines or topical corticosteroids) and short term (<30 days) prescription medications during the period 0 to 3 days before a study session (vitamin, herbal supplements and birth control medications not included).
- Donation or loss of greater than one pint of blood within 60 days of entry to the study.
- Any prior adverse reaction to lidocaine. Hypersensitivity to lidocaine, known history of hypersensitivity to local anesthetics of the amide type, other excipients in the patches tested or to adhesives on tapes used to cover or tape strip treatment sites.
- Received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month before enrollment in this study or expects to receive an experimental agent during the study.
- Any condition that would, in the opinion of the Medically Accountable Investigator (MAI), place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
- Consumption of alcohol within 24 h prior to dose administration.
- History as either reported by the subject or evident to the investigator of infectious disease or skin infection or of chronic skin disease (e.g., diabetes, psoriasis, atopic dermatitis).
- Hereditary skin disorders or any skin inflammatory conditions as reported by the research participant or evident to the MAI.
- History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma) except basal cell carcinomas that were superficial and did not involve the investigative sites.
- Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at application site (volar forearms/upper arms), sunburn, raised moles and scars, open sores at application site (volar forearms/upper arms), scar tissue, tattoo or coloration that would interfere with placement of formulations, skin assessment or reactions to lidocaine.
- BMI ≥30 kg/m2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: name brand patch
name brand lidocaine patch
|
lidocaine patch
Other Names:
|
OTHER: generic patch
generic lidocaine patch
|
lidocaine patch
Other Names:
|
OTHER: name brand patch-early
name brand lidocaine patch-early
|
lidocaine patch
Other Names:
|
OTHER: name brand patch-late
name brand lidocaine patch-late
|
lidocaine patch
Other Names:
|
OTHER: generic patch-early
generic lidocaine patch-early
|
lidocaine patch
Other Names:
|
OTHER: generic patch-late
generic lidocaine patch-late
|
lidocaine patch
Other Names:
|
OTHER: both patches
brand name and generic lidocaine patch
|
lidocaine patch
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of Maximum Serum Concentration (Cmax)
Time Frame: six study sessions for each participant; through 15 h each study session
|
maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered
|
six study sessions for each participant; through 15 h each study session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Audra Stinchcomb, PhD, University of Maryland Baltimore School of Pharmacy
- Principal Investigator: Hazem Hassan, PhD, University of Maryland Baltimore School of Pharmacy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 14, 2016
Primary Completion (ACTUAL)
January 10, 2019
Study Completion (ACTUAL)
May 15, 2020
Study Registration Dates
First Submitted
May 3, 2017
First Submitted That Met QC Criteria
May 8, 2017
First Posted (ACTUAL)
May 9, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 9, 2020
Last Update Submitted That Met QC Criteria
June 24, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- HP-00067033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heat Effect
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)CompletedHeat EffectUnited States
-
University of California, DavisCompletedEffect of Patient Position on Airway Heat Content
-
University of North Carolina, GreensboroStatim Technologies, LLCCompletedCryotherapy EffectUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...CompletedAnalysis of Neuromuscular Responses and the Balance After the Application of Physiotherapy ResourcesCryotherapy Effect | Musculoskeletal Injuries | Complication of Diathermy ProcedureBrazil
-
Erasmus Medical CenterRecruitingHeat Illness | Heat Exhaustion | Heat Stroke ExertionalNetherlands
-
Direction Centrale du Service de Santé des ArméesCompletedHeat Stress | HeatFrance
-
Johns Hopkins UniversityAga Khan University; Aman FoundationCompletedHeat Illness | Heat | Heat Exposure | Heat Stroke | Heat Exhaustion | Heat Syncope, Sequela | Heat Collapse | Heat Stroke and SunstrokePakistan
-
University of ConnecticutUnited States Department of DefenseRecruitingHeat Intolerance | Heat Stress | Fatigue; HeatUnited States
-
Petros DinasCompleted
Clinical Trials on Lidocaine patch
-
Aswan University HospitalUnknownCesarean Section ComplicationsEgypt
-
CRI LifetreeNuvo Research Inc.Completed
-
Scilex Pharmaceuticals, Inc.Completed
-
Corporacion Parc TauliCompletedDiabetic Neuropathy | Diabetic Nerve Problems | Diabetic Complications NeurologicalPakistan
-
Scilex Pharmaceuticals, Inc.Completed
-
Scilex Pharmaceuticals, Inc.Completed
-
Oregon Health and Science UniversityCompleted
-
Scilex Pharmaceuticals, Inc.Completed
-
Scilex Pharmaceuticals, Inc.Completed
-
Nicole K BrogdenLong Island UniversityCompleted